Collaborations & Alliances

Loxo Oncology Enters Strategic Pact with AmoyDx, PREMIA

To provide large-scale cancer patient screening in Asia to support the ongoing clinical development of LOXO-292

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Co., has entered into a strategic partnership agreement with AmoyDx and PREMIA Holdings, under which, AmoyDx and PREMIA will provide large-scale cancer patient screening in Asia to support the ongoing clinical development of LOXO-292, Loxo Oncology’s RET (rearranged during transfection) kinase inhibitor which leverages AmoyDx’s multi-gene polymerase chain reaction (PCR) and next-gen sequencing (NGS) panels to identify patients with ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters